[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100280652":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":31,"locations":36,"responsibleParty":50,"collaborators":21,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":21,"acronym":21,"eligibilityCriteria":58,"healthyVolunteers":55,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":21,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":21,"overallStatus":73,"whyStopped":21,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Shandong University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"H. pylori eradication cohort","EXPERIMENTAL","H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin.\n\nIf failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication.",[13,14],"Device: biopsy","Drug: H. pylori eradication",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DEVICE","biopsy","patients enrolled in the study will receive gastroscopy and biopsies in order to evaluate status of pathology.",[9],null,{"type":23,"name":24,"description":11,"armGroupLabels":25,"otherNames":21},"DRUG","H. pylori eradication",[9],[27],{"name":28,"affiliation":29,"role":30},"Li Yanqing, MD, PhD","Qilu Hospital of Shandong University","PRINCIPAL_INVESTIGATOR",[32],{"name":28,"role":33,"phone":34,"phoneExt":21,"email":35},"CONTACT","86-531-82169236","liyanqing@sdu.edu.cn",[37],{"facility":38,"status":21,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":21},"Department of Gastroenterology, Qilu Hospital, Shandong University","Jinan","Shandong","250012","China","CN",{"type":45,"coordinates":46},"Point",[47,48],116.99722,36.66833,{"lat":48,"lon":47},{"type":30,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"Yanqing Li","Vice president of Qilu Hospital","100280652","phase-4-the-influence-of-helicobacter-pylori-eradication-on-gastric-pathology-a-long-term-prospective-cohort-study-100280652",false,"NCT02933229","The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study","Inclusion Criteria:\n\n* Patients with H. pylori infection;\n* Aged 18-65 years.\n\nExclusion Criteria:\n\n* Patients with gastrectomy, acute GI bleeding and advanced gastric cancer;\n* Conditions unsuitable for performance of gastroscopy, such as coagulopathy, impaired renal function;\n* Pregnancy or breastfeeding;\n* Inability to provide informed consent and other situations that could interfere with the examination or therapeutic protocol.","ALL","18 Years","60 Years",{"count":63,"type":64},300,"ESTIMATED","INTERVENTIONAL",[67],"PHASE4","Helicobacter pylori (H. pylori) infection, affecting an estimated 50% of the global population, is a main cause of chronic gastritis, peptic ulcers and gastric cancer. By causing progressive damage to the stomach and may eventually result in gastric atrophy, H. pylori infection has been demonstrated to be responsible for more than 95% of gastric malignancies",[70,71,72],"Helicobacter Pylori","the Operative Link on Gastric Intestinal Metaplasia","Operative Link on Gastric Intestinal Assessment","NOT_YET_RECRUITING","2016-10-12",{"date":76,"type":64},"2016-10-14",{"date":78,"type":21},"2016-10",{"date":80,"type":64},"2031-10",{"name":5,"class":6},1]